Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.

Madhusudan KabraTristan J BarberClotilde AllavenaAnne-Geneviève MarcelinSimona Di GiambenedettoJuan PasquauNicola GianottiJosep M LlibreDavid Rial-CresteloRosa De Miguel-BuckleyGary BlickMatthew TurnerCale HarrisonTammy WynneGustavo VerdierChris M ParryBryn JonesChinyere OkoliCynthia DonovanJulie PriestEmilio Letang

Published in: Open forum infectious diseases (2023)

Results suggest that prior M184V/I has minimal impact on virologic suppression after switching to DTG + 3TC and provide reassurance when considering switching regimens in virologically suppressed PWH with incomplete treatment history or limited treatment options.

Keyphrases

antiretroviral therapy
human immunodeficiency virus
hiv infected patients
hiv infected
hiv positive
hiv aids
hepatitis c virus
combination therapy